Palonosetron, a medication used to prevent nausea and vomiting associated with chemotherapy and surgery, was developed in the 1990s and approved for medical use in the early 2000s. Its history is marked by its effectiveness as a long-acting antiemetic, particularly due to its strong binding affinity and prolonged half-life, which distinguishes it from earlier treatments.
Palonosetron, a selective serotonin (5-HT3) receptor antagonist, was approved in the United States in 2003 and is widely used in both chemotherapy-induced and postoperative nausea and vomiting prevention. Its development highlighted improved patient outcomes with fewer dosing requirements, contributing to its inclusion in multiple clinical guidelines and combination therapies for supportive cancer care.
BRAND NAMES
Aloxi (most widely known international brand)
MECHANISM OF ACTION
The mechanism of action of Palonosetron lies in its selective blockade of serotonin (5-HT3) receptors present both centrally in the chemoreceptor trigger zone and peripherally on vagal nerve endings in the gastrointestinal tract. During chemotherapy or surgery, serotonin released from intestinal enterochromaffin cells binds to these receptors and initiates the vomiting reflex. Palonosetron inhibits this process by preventing serotonin from attaching to the receptors, thereby suppressing the transmission of emetic signals. Its high receptor affinity and prolonged duration of action contribute to sustained prevention of nausea and vomiting.
PHARMACOKINETICS
Absorption
Palonosetron is well absorbed following administration, with high bioavailability. After dosing, it reaches peak plasma concentrations relatively quickly, and its absorption is not significantly influenced by food. This efficient absorption contributes to its sustained therapeutic effect in preventing nausea and vomiting.
Distribution
Palonosetron has a large volume of distribution (approximately 6–8 L/kg), indicating extensive distribution into body tissues beyond the plasma. This wide distribution supports its prolonged duration of action and effectiveness at both central and peripheral receptor sites involved in nausea and vomiting control.
Metabolism
Palonosetron is primarily metabolized in the liver by the cytochrome P450 system, mainly through CYP2D6, with minor involvement of CYP3A4 and CYP1A2. It is converted into inactive metabolites, while a significant portion of the drug is excreted unchanged, contributing to its long-lasting antiemetic effect.
Elimination
Palonosetron is eliminated from the body through both renal and hepatic pathways. Approximately 40% of the administered dose is excreted unchanged in the urine, while the remainder is metabolized in the liver and excreted in the urine or feces as inactive metabolites. Its long elimination half-life, around 40 hours, supports sustained antiemetic effects with single-dose administration.
PHARMACODYNAMICS
Palonosetron exerts its effects by selectively antagonizing serotonin (5-HT3) receptors in both the central nervous system and the gastrointestinal tract. By blocking these receptors, it prevents serotonin released during chemotherapy or surgery from triggering the vomiting reflex. Palonosetron is distinguished by its high receptor binding affinity, allosteric binding, and ability to induce receptor internalization, which prolongs its antiemetic action. These properties make it effective in preventing both acute and delayed nausea and vomiting, often with a single dose.
ADMINISTRATION
Palonosetron is commonly administered either intravenously (IV) or orally. For chemotherapy-induced nausea and vomiting, a single IV dose is typically given 30 minutes before the start of chemotherapy, while the oral form is taken about 1 hour prior. The dosing schedule may vary depending on the chemotherapy regimen, but due to its long half-life, repeated daily dosing is usually unnecessary. Proper timing ensures optimal prevention of both acute and delayed nausea and vomiting.
DOSAGE AND STRENGTH
Intravenous (IV) injection: 0.25 mg as a single dose, typically administered 30 minutes before chemotherapy.
Oral capsule: 0.5 mg, taken approximately 1 hour before chemotherapy.
DRUG INTERACTIONS
Palonosetron has low interaction potential but may be affected by strong CYP2D6 inhibitors or combined with other serotonergic or QT-prolonging drugs, though it is generally safe with most chemotherapy regimens.
FOOD INTERACTIONS
Palonosetron can be taken with or without food, as its absorption is not significantly affected by meals. This allows flexible administration without the need to adjust timing relative to eating.
CONTRAINDICATIONS
Palonosetron is contraindicated in patients with a known hypersensitivity to palonosetron or any component of the formulation. It should not be used in individuals with severe hypersensitivity reactions to other 5-HT3 receptor antagonists, as cross-reactivity may occur.
SIDE EFFECTS
Headache
Constipation
Fatigue or weakness
Dizziness
Diarrhea
Transient QT interval prolongation
Rare severe allergic reactions (hypersensitivity)
OVERDOSE
In cases of Palonosetron overdose, symptoms are generally mild due to its wide therapeutic index but may include headache, constipation, dizziness, or transient changes in heart rhythm (QT prolongation). There is no specific antidote, so treatment is supportive and symptomatic, with careful monitoring of vital signs and cardiac function if needed.
TOXICITY
Palonosetron has a low toxicity profile. Animal and human studies indicate that even at doses higher than the therapeutic range, serious adverse effects are uncommon. Potential toxic effects are primarily cardiac (QT interval prolongation), gastrointestinal (constipation, diarrhea), and neurological (headache, dizziness). Severe toxicity is rare, making Palonosetron generally safe for clinical use when dosed appropriately.
